FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025646009> ?p ?o ?g. }

• W3025646009 endingPage "391" @default.
• W3025646009 startingPage "378" @default.
• W3025646009 abstract "Abstract Background Germ cell tumours (GCTs) are the most common solid malignancies in young men. Although high cure rates can be achieved, metastases, resistance to cisplatin-based therapy and late toxicities still represent a lethal threat, arguing for the need of new therapeutic options. In this study, we analysed the potential of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib (PaRi) as molecular drugs to treat cisplatin-resistant and -sensitive paediatric and adult GCTs. Methods Ten GCT cell lines, including cisplatin-resistant subclones and non-malignant controls, were treated with PaRi and screened for changes in viability (triphenyl tetrazolium chloride (XTT) assay), apoptosis rates (flow cytometry, caspase assay), the cell cycle (flow cytometry), the transcriptome (RNA-sequencing, quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and on protein level (western blot). Expression profiling was performed on paediatric and adult GCT tissues (expression microarrays, qRT-PCR, immunohistochemistry, ‘The Cancer Genome Atlas’ database). Results We demonstrate that adult GCTs highly express CDK4 , while paediatric GCTs strongly express CDK6 instead. Thus, both GCT types are potentially treatable by PaRi. GCTs presented as highly sensitive towards PaRi, which caused a decrease in viability, cell cycle arrest and apoptosis. Although GCTs mainly arrested in the G1/G0 phase, some embryonal carcinoma cell lines were able to bypass the G1/S checkpoint and progressed to the G2/M phase. We found that upregulation of CDK3 and downregulation of many mitosis regulation factors, like the HAUS genes, might be responsible for bypassing the G1/S checkpoint and termination of mitosis, respectively. We postulate that GCT cells do not tolerate these alterations in the cell cycle and eventually induce apoptosis. Conclusion Our study highlights PaRi as therapeutic options for cisplatin-resistant and -sensitive paediatric and adult GCTs." @default.
• W3025646009 created "2020-05-21" @default.
• W3025646009 creator A5000431294 @default.
• W3025646009 creator A5012999053 @default.
• W3025646009 creator A5018790364 @default.
• W3025646009 creator A5022660425 @default.
• W3025646009 creator A5028366217 @default.
• W3025646009 creator A5031271300 @default.
• W3025646009 creator A5033100401 @default.
• W3025646009 creator A5051141861 @default.
• W3025646009 creator A5066191006 @default.
• W3025646009 creator A5068364488 @default.
• W3025646009 creator A5068715101 @default.
• W3025646009 date "2020-05-18" @default.
• W3025646009 modified "2023-10-09" @default.
• W3025646009 title "CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms" @default.
• W3025646009 cites W1517981219 @default.
• W3025646009 cites W1571624349 @default.
• W3025646009 cites W1968713298 @default.
• W3025646009 cites W1984245506 @default.
• W3025646009 cites W2006237067 @default.
• W3025646009 cites W2026084160 @default.
• W3025646009 cites W2052972341 @default.
• W3025646009 cites W2053289102 @default.
• W3025646009 cites W2085189545 @default.
• W3025646009 cites W2119221379 @default.
• W3025646009 cites W2121293811 @default.
• W3025646009 cites W2126821691 @default.
• W3025646009 cites W2133465414 @default.
• W3025646009 cites W2153020542 @default.
• W3025646009 cites W2158217645 @default.
• W3025646009 cites W2259949170 @default.
• W3025646009 cites W2275884422 @default.
• W3025646009 cites W2284518822 @default.
• W3025646009 cites W2294604545 @default.
• W3025646009 cites W2295971206 @default.
• W3025646009 cites W2309969893 @default.
• W3025646009 cites W2410675266 @default.
• W3025646009 cites W2476327911 @default.
• W3025646009 cites W2509430819 @default.
• W3025646009 cites W2522030015 @default.
• W3025646009 cites W2562317580 @default.
• W3025646009 cites W2568050301 @default.
• W3025646009 cites W2792955409 @default.
• W3025646009 cites W2793671087 @default.
• W3025646009 cites W2805901899 @default.
• W3025646009 cites W2807733000 @default.
• W3025646009 cites W2897283312 @default.
• W3025646009 cites W2900569176 @default.
• W3025646009 cites W2900790986 @default.
• W3025646009 cites W2905067827 @default.
• W3025646009 cites W2912564218 @default.
• W3025646009 cites W2914719317 @default.
• W3025646009 cites W2971699123 @default.
• W3025646009 cites W3104123570 @default.
• W3025646009 cites W4211258097 @default.
• W3025646009 doi "https://doi.org/10.1038/s41416-020-0891-x" @default.
• W3025646009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7403155" @default.
• W3025646009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32418994" @default.
• W3025646009 hasPublicationYear "2020" @default.
• W3025646009 type Work @default.
• W3025646009 sameAs 3025646009 @default.
• W3025646009 citedByCount "25" @default.
• W3025646009 countsByYear W30256460092020 @default.
• W3025646009 countsByYear W30256460092021 @default.
• W3025646009 countsByYear W30256460092022 @default.
• W3025646009 countsByYear W30256460092023 @default.
• W3025646009 crossrefType "journal-article" @default.
• W3025646009 hasAuthorship W3025646009A5000431294 @default.
• W3025646009 hasAuthorship W3025646009A5012999053 @default.
• W3025646009 hasAuthorship W3025646009A5018790364 @default.
• W3025646009 hasAuthorship W3025646009A5022660425 @default.
• W3025646009 hasAuthorship W3025646009A5028366217 @default.
• W3025646009 hasAuthorship W3025646009A5031271300 @default.
• W3025646009 hasAuthorship W3025646009A5033100401 @default.
• W3025646009 hasAuthorship W3025646009A5051141861 @default.
• W3025646009 hasAuthorship W3025646009A5066191006 @default.
• W3025646009 hasAuthorship W3025646009A5068364488 @default.
• W3025646009 hasAuthorship W3025646009A5068715101 @default.
• W3025646009 hasBestOaLocation W30256460091 @default.
• W3025646009 hasConcept C105696609 @default.
• W3025646009 hasConcept C124320809 @default.
• W3025646009 hasConcept C190283241 @default.
• W3025646009 hasConcept C199649820 @default.
• W3025646009 hasConcept C2776694085 @default.
• W3025646009 hasConcept C2778239845 @default.
• W3025646009 hasConcept C29537977 @default.
• W3025646009 hasConcept C502942594 @default.
• W3025646009 hasConcept C53227056 @default.
• W3025646009 hasConcept C54355233 @default.
• W3025646009 hasConcept C62112901 @default.
• W3025646009 hasConcept C86803240 @default.
• W3025646009 hasConcept C93304396 @default.
• W3025646009 hasConcept C95444343 @default.
• W3025646009 hasConceptScore W3025646009C105696609 @default.
• W3025646009 hasConceptScore W3025646009C124320809 @default.
• W3025646009 hasConceptScore W3025646009C190283241 @default.
• W3025646009 hasConceptScore W3025646009C199649820 @default.

• next